Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

DiabetologNytt Nr 1-2-2025
Senaste Nr DiabetologNytt i PDF
Arkiv alla nyheter

Metoclopramide Nasal Spray Shows Promise for Diabetic Gastroparesis. Phase 2 study

Reuters – A phase 2b study has found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis than oral metoclopramide, Evoke Pharma Inc said today.

The study compared the efficacy and safety of metoclopramide nasal spray dosed four times a day for six weeks to oral metoclopramide in 89 diabetic patients with symptoms of gastroparesis.

Gastroparesis is a condition in which the muscles of the stomach work slowly and lead to slow emptying of food from the stomach into the intestine. Diabetes is the most common cause for the condition.

Metoclopramide nasal spray provided better symptom control than oral metoclopramide,” the authors report in Neurogastroenterology & Motility, online now.

The side-effect profile of metoclopramide nasal spray was ”favorable. More side effects, especially nausea, occurred with the oral tablets,” they note.

”It is intuitive that a nasal spray will have more reliable absorption than a tablet in patients with delayed gastric emptying, Dr. Marilyn Carlson, Chief Medical Officer of Evoke Pharmaceuticals, said in a statement.

”These data from symptomatic diabetic gastroparesis patients confirm that metoclopramide nasal spray is well-tolerated and can offer better symptom relief than a tablet in this population,” she added. ”We believe the results from our Phase 2b clinical trial validate our novel intranasal delivery system of metoclopramide (EVK-001) which will be evaluated soon in our upcoming Phase 3 clinical trial,” said Dave Gonyer, President and Chief Executive Officer of Evoke.

”There haven’t been any new drugs for the management of symptoms associated with gastroparesis approved by the FDA since 1980, and there are very few drugs in clinical development for this debilitating diabetic complication,” he added.

Neurogastroenterol Motil Dec 2013.

From Reuters Health

 

Facebook
LinkedIn
Email
WhatsApp